Biomarker-Driven Lung Cancer

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab (Opdivo) in previously treated advanced non-small cell lung cancer (NSCLC).

Jason Chesney, MD, PhD, has been appointed director of the University of Louisville’s James Graham Brown Cancer Center.

Ceritinib (Zykadia) has been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use for the treatment of patients with ALK-positive, metastatic non–small cell lung cancer.

The genetic profile of treatment-resistant non-small cell lung cancer may be more complex than initially thought, according to a presentation by Zofia Piotrowska, MD.

Rafal Dziadziuszko, MD, PhD, a global leader in clinical thoracic oncology, was recently honored with the 2017 Heine H. Hansen Award by ESMO and the IASLC. 

More Stage I cancers were diagnosed after the passage of the Affordable Care Act within 5 screenable disease types (colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer) than were diagnosed before ACA implementation.

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses why CheckMate-026 was not successful in showing an improvement in progression-free survival (PFS) for patients with advanced non-small cell lung cancer.

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.

Ramaswamy Govindan, MD, speaks to the rapid therapeutic changes and sequencing questions physicians are currently asking.

Pembrolizumab (Keytruda) has been granted an accelerated approval by the FDA for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer, regardless of PD-L1 expression.

Anna Farago, MD, PhD, discusses a phase I study of olaparib (Lynparza) and temozolomide (Temodar) in patients with small cell lung cancer who had progression after 1 prior line of platinum-based chemotherapy.

The safety and tolerability of chimeric antigen receptor T-cell therapy is being explored in an ongoing single-arm, phase I clinical trial for patients with advanced non–small cell lung cancer.

Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in NSCLC and what researchers are poised to do next in the field.

Siddhartha Devarakonda, MD, highlights the importance of testing for molecular markers, some of the rarer mutations, and what work lies ahead for the field of NSCLC.

Stereotactic body radiotherapy is safe and effective in patients ≥80 years with early-stage non–small cell lung cancer, results of a multi-center retrospective analysis showed.

Jonathan Riess, MD, discusses the game-changing efficacy of osimertinib in NSCLC and its potential in combination, considering factors for choosing an EGFR TKI, and the burgeoning questions clinicians still have with the<em> EGFR</em>-mutant population.

Brigatinib has been granted an accelerated approval by the FDA as a treatment for patients with metastatic <em>ALK</em>-positive non&ndash;small cell lung cancer who are resistant to prior crizotinib.

The molecular profile of a patient with cancer who is about to be treated for their metastatic disease is the most critical piece of information you can have for that patient, according to Howard A. &ldquo;Skip&rdquo; Burris III, MD.

Lorlatinib has been granted a breakthrough therapy designation by the FDA for use in patients with <em>ALK</em>-positive metastatic non-small cell lung cancer who have previously received 1 or more ALK inhibitors.

Osimertinib has been granted a full approval by the European Union for the treatment of patients with locally advanced or metastatic <em>EGFR T790M&nbsp;</em>mutation-positive non&ndash;small cell lung cancer, regardless of prior treatment with an EGFR TKI.

Matthew Gubens, MD, sheds light on how far the field has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Immunotherapy has made a significant impact in the field of non&ndash;small cell lung cancer. However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced disease.

Veliparib fell short of meeting the primary endpoint&nbsp;in a phase III non&ndash;small cell lung cancer trial and a triple-negative breast cancer trial.

Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.

Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non-Small Cell Lung Cancer